BioAegis Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $20M

  • Investors
  • 3

BioAegis Therapeutics General Information

Description

Operator of a clinical-stage drug development company intended to facilitate the treatment of inflammation and infectious diseases. The company specializes in the research of drugs to restore plasma gelsolin an innate immunity that provides an immunotherapeutic approach to fighting pathogens, enabling patients suffering from severe conditions with high unmet medical needs to receive biomarker-directed treatments across a range of indications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Commercialization Center for Innovative Technology
  • 685 US Route 1
  • North Brunswick, NJ 08902
  • United States
+1 (973)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Commercialization Center for Innovative Technology
  • 685 US Route 1
  • North Brunswick, NJ 08902
  • United States
+1 (973)

BioAegis Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioAegis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 16-Oct-2023 $20M Completed Clinical Trials - Phase 2
9. Later Stage VC 22-Mar-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 31-Dec-2021 Completed Clinical Trials - Phase 2
7. Later Stage VC 07-Oct-2020 Completed Clinical Trials - Phase 2
6. Debt - PPP 28-Apr-2020 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 01-Aug-2018 Completed Clinical Trials - General
4. Grant 09-Jul-2016 Completed Clinical Trials - General
3. Later Stage VC 11-Mar-2016 Completed Startup
2. Early Stage VC (Series A) 01-Jan-2015 $8.04M $11M Completed Startup
1. Angel (individual) 08-Feb-2013 $3M $3M Completed Startup
To view BioAegis Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BioAegis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage drug development company intended to facilitate the treatment of inflammation and infectiou
Drug Discovery
North Brunswick, NJ
12 As of 2025

Lausanne, Switzerland
 

Zurich, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioAegis Therapeutics Competitors (14)

One of BioAegis Therapeutics’s 14 competitors is Asceneuron, a Venture Capital-Backed company based in Lausanne, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Asceneuron Venture Capital-Backed Lausanne, Switzerland
Endogena Therapeutics Venture Capital-Backed Zurich, Switzerland
Alkahest Formerly VC-backed San Carlos, CA
AviadoBio Venture Capital-Backed London, United Kingdom
Inflammasome Therapeutics Venture Capital-Backed Newton, MA
You’re viewing 5 of 14 competitors. Get the full list »

BioAegis Therapeutics Patents

BioAegis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021347408-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020
AU-2021347408-A9 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020
EP-4204818-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020
CA-3196026-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020
US-20230398176-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 A61K38/16
To view BioAegis Therapeutics’s complete patent history, request access »

BioAegis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioAegis Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biomedical Advanced Research and Development Authority Government
European Investment Fund Fund of Funds Minority
National Institute Of Allergy and Infectious Diseases Government
To view BioAegis Therapeutics’s complete investors history, request access »

BioAegis Therapeutics FAQs

  • When was BioAegis Therapeutics founded?

    BioAegis Therapeutics was founded in 2011.

  • Where is BioAegis Therapeutics headquartered?

    BioAegis Therapeutics is headquartered in North Brunswick, NJ.

  • What is the size of BioAegis Therapeutics?

    BioAegis Therapeutics has 12 total employees.

  • What industry is BioAegis Therapeutics in?

    BioAegis Therapeutics’s primary industry is Drug Discovery.

  • Is BioAegis Therapeutics a private or public company?

    BioAegis Therapeutics is a Private company.

  • What is BioAegis Therapeutics’s current revenue?

    The current revenue for BioAegis Therapeutics is .

  • How much funding has BioAegis Therapeutics raised over time?

    BioAegis Therapeutics has raised $56.7M.

  • Who are BioAegis Therapeutics’s investors?

    Biomedical Advanced Research and Development Authority, European Investment Fund, and National Institute Of Allergy and Infectious Diseases have invested in BioAegis Therapeutics.

  • Who are BioAegis Therapeutics’s competitors?

    Asceneuron, Endogena Therapeutics, Alkahest, AviadoBio, and Inflammasome Therapeutics are some of the 14 competitors of BioAegis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »